**NM signifies a non meaningful value. A dash signifies the data is not available.

Between 3% and 5% of colorectal cancers exhibit the KRAS G12C mutation. Credit: SewCreamStudio/Shutterstock. Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

The U.S. Food and Drug Administration (FDA) gave Amgen (NASDAQ:AMGN) approval to use its KRASG12C inhibitor Lumakras with Vectibix for treating advanced colorectal cancer. Warning! GuruFocus has ...

The FDA on Thursday agreed to expand the label of Amgen’s KRAS inhibitor Lumakras (sotorasib), opening up its use in colorectal cancer. With the latest approval, Lumakras can now be combined with ...

Today, a brief rundown of news involving Novo Nordisk and AstraZeneca, as well as updates from Amgen, Atara Biotherapeutics and Boehringer Ingelheim that you may have missed. Patents protecting ...

His career has included stops at Eli Lilly, Novian Health and, for the last 16 years, Amgen. His tenure at Amgen included roles in sales and marketing for many of its hematology and oncology ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...